There are four active trials including patients with SCLC investigating CAR-T cell therapies (Figure 4 and Table 5): anti-DLL3 NK cells, anti-DLL3 CAR-T cells, and anti-gangliosides disialoganglioside GD2 (GD2) and iC9 CAR-T cells. Here, DLL3 is linked to small cell lung carcinoma.